RxDoctor Payments Data

Shobha Patel, MD

Internal Medicine · Southampton, NYNPI 1225052897

Payments from drug & device makers

$2,816in general payments, 2019–2025

Across 114 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$481
  • AstraZeneca$437
  • Regeneron Healthcare Solutions, Inc.$387
  • Pfizer$276
  • Lundbeck LLC$237
  • Novo Nordisk$146
  • plus $852 from 18 others

What the payments were for

  • Food & beverage$2,77098%
  • Education$462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,816 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$153,097
Medicare patients
553
Services billed
1,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$67,172
EliquisApixaban59$62,172
XareltoRivaroxaban29$36,014
JanuviaSitagliptin Phosphate20$26,963
JardianceEmpagliflozin20$25,863
SynjardyEmpagliflozin/Metformin Hcl23$22,309
Xigduo XrDapaglifloz Propaned/Metformin12$19,433
FarxigaDapagliflozin Propanediol13$16,963
SynthroidLevothyroxine Sodium92$6,694
Tresiba Flextouch U-100Insulin Degludec13$6,268
Levothyroxine Sodium316$5,266
SymbicortBudesonide/Formoterol Fumarate12$4,677
Rosuvastatin Calcium247$3,979
Atorvastatin Calcium270$3,361
Pantoprazole Sodium143$2,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$146$67,17260 claims
PfizerEliquis$276$62,17259 claims
Boehringer IngelheimJardiance, Synjardy$87$48,17243 claims
Johnson & JohnsonXarelto$137$36,01429 claims
AstraZenecaFarxiga, Symbicort$437$21,64025 claims
AbbVieSynthroid$481$6,69492 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$5,266316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Southampton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →